Sitemap
Update: July 26th, 2009
Sitemap of posts on Orshe.com
Posts
- Category: Wall Street Journal (continued)
- AM Report: Will Health Summit Work?
- AMA Looks to Put Brakes on Debt Load of Med Students
- AMA on End-of-Life Debate: ‘Egregious … Mischaracterization’
- AMA Prez-Elect: What Docs Want In Exchange for Curbing Costs
- AMA Weighs Whether Docs Should Hang Up Their White Coats
- AMA, Hospitals Back Senate Health Bill; Insurers Still Opposed
- AMA: the White Coats Are Going, the White Coats Are Going
- Americans Spend $34 Billion a Year on ‘Alternative’ Medicine
- Amgen Gets a Lift
- Amgen, GSK to Launch Joint Sales Attack for Bone Drug
- Amid Reform Talk, Alternative Medicine Gets Some Love
- An ER Doc Grapples With ‘Unnecessary’ Hospital Admissions
- An M.D. On How Money Drives Medical Testing
- Analysts Like J&J’s Deal for Cougar
- Analysts React to FDA Panel: ‘It Wasn’t a Perfect Day for Amgen’
- Anatomy of a Market: Shedding Light on Cadaver Commerce
- And Here’s the Bill to Block Medicare Pay Cuts to Doctors
- And Sanofi Makes Three: More Data That One Shot Will Do Against Swine Flu
- Another Cholesterol Drug to Join the U.S. Market
- Another Diabetes Drug is Linked to Pancreas Inflammation
- Another Emory Psychiatrist Draws Fire for Payments From Glaxo
- Another Health-Care Bill Detail: Cap On Flex Spending Accounts
- Another Japanese Drugmaker Makes Another Foreign Acquisition
- Another Potential Plavix Competitor: AstraZeneca’s Brilinta
- Antidepressant Alternative for Pregnant Women: Shock Therapy
- Antipsychotic Drugs, Elderly Patients and Omnicare’s Settlement
- Antipsychotics, Diabetes & Kids
- Antipsychotics, Nursing Homes and the Feds’ Case Against J&J
- Apple’s Steve Jobs on Course to End Medical Leave
- Applying for Residencies, Med School Grads Are Put On the Spot
- Approval of Effient, a Plavix Rival, Boosts Japanese Drug Maker
- Are Mammograms and PSA Tests Overrated?
- Army Says Faked Medical Study Involves ‘Ghost’ Soldiers
- As Food-Safety Push Grows, Consumers Sort Out Dos, Don’ts
- As Health Costs Bite Aetna, Analysts Downgrade Stock
- As Health-Care Finale Gets Closer, Both Sides Boost Spending
- As Medicare Feels Pinch, Sebelius Puts Health-Reform Odds at 75-25
- As Woods Apologizes, What Doctors Have to Say About Sex Addiction
- ASCO: New Research on Breast, Stomach and Lung Cancers
- Aspirin Blocking Blood Clots: For Some, It Doesn’t Work
- Assigning an Apgar Score to Newborns
- AstraZeneca Chalks Up Seroquel Dismissal in State Court
- AstraZeneca to Cut Another 8,000 Jobs
- At Top Schools, More Than Half the Profs Have Industry Ties
- Back to School: Kids Play More Tag At Recess, Fight Less
- Bacteria More Diabolical Than We Think
- Bacteria Spread More Than Disease
- Baucus Bill Unveiled: No Government Insurance Option
- Baucus Compromises on Health Bill
- Baucus Health Bill: 564 Proposed Amendments, and Counting
- Baucus Says $1 Trillion Health-Reform Overhaul Is Possible
- Baucus Tweaks Health-Care Bill to Win Broader Support
- Baucus, Grassley Slam Physician-Owned Hospitals
- Baucus: Don’t Like Comparative Effectiveness? Meet ‘Fred’
- Behind the Health Debate: The Role of Government
- Being a Sports Team Doctor Has Its Pressures
- Beyond that Town Hall: Barney Frank’s Medical Marijuana Bill
- Bi-Partisan Challenges to Obama Health Plan
- Big Bang Theory for July 4: Leave It to the Professionals
- Big Pharma Adds to Generics Medicine Chest
- Big Pharma Looks To Branded Generics In Developing World
- Big Pharma, Generic Competition and Cash
- Billionaire Doc Offers $100 Million Guaranty to Re-Open Hospital
- Biogen Idec, Genzyme and the Struggles of Big Biotech
- Biotech News: Provenge for Prostate Cancer, Tysabri for M.S.
- Blue Shield Wins Case Over Rescinded Health Insurance
- Boosting Medical Students’ Training in Drug Abuse
- Boston Medical School in Awkward Spot After Craigslist Arrest
- Boston Scientific Cuts Jobs; Defibrillator Safety Questioned
- Boston Scientific Gets Good Data on Heart-Tuning Device
- Boston Scientific Sets $296 Million Settlement on Devices
- Boston Scientific, J&J Deal is Latest Sign of Stent Suit Detente
- Boston Scientific-Guidant Deal: Not the Worst of the Decade!
- Botox Gets Stuck With Black-Box Warning
- Botox Reduces Headache for Patients, Allergan

